Acute Myeloid Leukemia (AML) Treatment Market size in APAC to grow by USD 277.03 Million | Driven by high incidence of acute myeloid leukemia | Technavio
NEW YORK, March 7, 2022 /PRNewswire/ -- "Acute Myeloid Leukemia (AML) Treatment Market in APAC by Type and Geography - Forecast and Analysis 2022-2026" has been added to Technavio's offering. The market is expected to witness a YOY growth of 12.56% in 2022 and is anticipated to grow at a CAGR of 12.83% between 2021 and 2026. The report segments the market by type (chemotherapy, stem cell transplantation, and others) and geography (China, Japan, India, and Rest of APAC).
For more insights on YOY and CAGR, Read our FREE Sample Report
Vendor Insights
The acute myeloid leukemia (AML) treatment market in APAC is fragmented due to the presence of many local and global players. These vendors are consistently investing in the latest technologies to develop advanced treatment options for AML. Vendors are partnering with research organizations and hospitals for R&D and are participating in various scientific conferences to showcase their products. They are also focusing on other aspects such as product approvals, M&A, and new product launches to gain a competitive edge in the market.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
- AbbVie Inc.
- Agios Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Co.
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Find additional highlights on the growth strategies adopted by vendors and their product offerings, Read Free Sample Report.
Regional Market Analysis
China will provide maximum growth opportunities for market vendors during the forecast period. According to our research report, the country will contribute to 40% of the global market growth and is expected to dominate the market through 2026. The increasing demand for personalized drugs and the expected approvals between 2020 and 2023 of several therapies will be crucial in driving the growth of the acute myeloid leukemia (AML) treatment market in APAC. However, the market will witness faster growth in India during the forecast period.
Know more about this market's geographical distribution along with the detailed analysis of the top regions. https://www.technavio.com/report/acute-myeloid-leukemia-aml-treatment-market-industry-in-apac-analysis
Key Segment Analysis
By type, the market share by the chemotherapy segment will be significant during the forecast period. The growth of the segment can be attributed to the availability of many chemotherapy drugs for AML in APAC. Also, the presence of large pharmaceutical players such as Novartis AG, Pfizer Inc., Teva Pharmaceuticals, AbbVie Inc, with highly effective chemotherapy drugs for the treatment of AML will be crucial in driving the growth of the segment.
View FREE Sample: to know additional highlights and key points on various market segments and their impact in coming years.
Key Market Drivers & Challenges:
The acute myeloid leukemia (AML) treatment market is primarily driven by the high incidence of AML. Countries in APAC have been experiencing a rise in the number of AML cases over the years. For instance, in 2021, the estimated number of new cases in Australia was 4,903. Similarly, every year in New Zealand, around 700 adults and 40 children are diagnosed with leukemia. The high incidence of the condition is increasing the demand for drugs to treat AML, which is driving the growth of the market.
However, the lack of adequate healthcare infrastructure in many developing countries in APAC will reduce the growth potential in the market. Many developing and underdeveloped economies in APAC lack proper healthcare infrastructure due to limited healthcare budgets. This has limited the number of healthcare institutions that use advanced radiotherapy systems for cancer treatment, which is expected to have a negative impact on the growth of the market.
Download a free sample for highlights on market Drivers & Challenges affecting the acute myeloid leukemia (AML) treatment market.
Customize Your Report
Don't miss out on the opportunity to speak to our analyst and know more insights about this market report. Our analysts can also help you customize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
We offer USD 1,000 worth of FREE customization at the time of purchase. Speak to our Analyst now!
Related Reports:
Monoclonal Antibodies Market by Application and Geography Forecast and Analysis 2022-2026
Acute Myeloid Leukemia (AML) Treatment Market in APAC: Scope | |
Report Coverage | Details |
Page number | 120 |
Base year | 2021 |
Forecast period | 2022-2026 |
Growth momentum & CAGR | Accelerate at a CAGR of 12.83% |
Market growth 2022-2026 | USD 277.03 million |
Market structure | Fragmented |
YoY growth (%) | 12.56 |
Regional analysis | China, Japan, India, and Rest of APAC |
Performing market contribution | China at 40% |
Key consumer countries | China, Japan, India, and Rest of APAC |
Competitive landscape | Leading companies, competitive strategies, consumer engagement scope |
Companies profiled | AbbVie Inc., Agios Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Daiichi Sankyo Co. Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. |
Market Dynamics | Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Table of Contents:
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
2. Market Landscape
2.1 Market ecosystem
Exhibit 07: Parent market
Exhibit 08: Market Characteristics
2.2 Value Chain Analysis
Exhibit 09: Value chain analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery
2.2.2 Integration and product development
2.2.3 Manufacturing
2.2.4 Outbound logistics
2.2.5 Marketing and sales
2.2.6 Support activities
2.2.7 Innovation
3. Market Sizing
3.1 Market definition
Exhibit 10: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 11: Market segments
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
3.4.1Estimating growth rates for emerging and high-growth markets
3.4.2 Estimating growth rates for mature markets
Exhibit 12: Global - Market size and forecast 2021 - 2026 (million $)
Exhibit 13: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 14: Five forces analysis 2021 - 2026
4.2 Bargaining power of buyers
Exhibit 15: Bargaining power of the buyer
4.3 Bargaining power of suppliers
Exhibit 16: Bargaining power of the supplier
4.4 Threat of new entrants
Exhibit 17: Threat of new entrants
4.5 Threat of substitutes
Exhibit 18: Threat of substitutes
4.6 Threat of rivalry
Exhibit 19: Threat of rivalry
4.7 Market condition
Exhibit 20: Market condition - Five forces 2021
5. Market Segmentation by Type
5.1 Market segments
Exhibit 21: Type- Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 22: Comparison by Type
5.3 Chemotherapy - Market size and forecast 2021-2026
Exhibit 23: Chemotherapy- Market size and forecast 2021-2026 ($ billion)
Exhibit 24: Chemotherapy- Year-over-year growth 2021-2026 (%)
5.4 Stem cell transplantation - Market size and forecast 2021-2026
Exhibit 25: Stem cell transplantation - Market size and forecast 2021-2026 ($ billion)
Exhibit 26: Stem cell transplantation- Year-over-year growth 2021-2026 (%)
5.5 Others - Market size and forecast 2021-2026
Exhibit 27: Others - Market size and forecast 2021-2026 ($ billion)
Exhibit 28: Others- Year-over-year growth 2021-2026 (%)
5.6 Market opportunity by Type
Exhibit 29: Market opportunity by Type
6. Customer landscape
Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
Exhibit 30: Customer landscape
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 31: Market share by geography 2021-2026 (%)
7.2 Geographic comparison
Exhibit 32: Geographic comparison
7.3 China - Market size and forecast 2021-2026
Exhibit 33: China - Market size and forecast 2021-2026 ($ million)
Exhibit 34: China - Year-over-year growth 2021-2026 (%)
7.4 Japan - Market size and forecast 2021-2026
Exhibit 35: Japan - Market size and forecast 2021-2026 ($ million)
Exhibit 36: Japan - Year-over-year growth 2021-2026 (%)
7.5 India - Market size and forecast 2021-2026
Exhibit 37: India - Market size and forecast 2021-2026 ($ million)
Exhibit 38: India - Year-over-year growth 2021-2026 (%)
7.6 Rest of APAC - Market size and forecast 2021-2026
Exhibit 39: Rest of APAC - Market size and forecast 2021-2026 ($ million)
Exhibit 40: Rest of APAC - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 41: Key leading countries
7.8 Market opportunity by geography
Exhibit 42: Market opportunity by geography ($ million)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 High incidence of acute myeloid leukemia
8.1.2 Advancements in pharmacology and molecular biology in APAC
8.1.3 Rising adoption of generic drugs
8.2 Market challenges
8.2.1 Lack of adequate healthcare infrastructure in developing nations
8.2.2 Complications related to chemotherapy
8.2.3 High cost of treatment
Exhibit 43: Impact of drivers and challenges
8.3 Market trends
8.3.1 CAR T-cell therapy for AML
8.3.2 Approval of new treatment methods
8.3.3 Increase in awareness programs
9. Vendor Landscape
9.1 Overview
Exhibit 44: Vendor landscape
9.2 Landscape disruption
Exhibit 45: Landscape disruption
Exhibit 46: Industry Risk
10. Vendor Analysis
10.1 Vendors Covered
Exhibit 47: Vendor Landscape
10.2 Market positioning of vendors
Exhibit 48: Market positioning of vendors
10.3 AbbVie Inc.
Exhibit 49: AbbVie Inc. - Overview
Exhibit 50: AbbVie Inc. - Business segments
Exhibit 51: AbbVie Inc. - Key offerings
Exhibit 52: AbbVie Inc. - Segment focus
10.4 Agios Inc.
Exhibit 53: Agios Inc. - Overview
Exhibit 54: Agios Inc. - Business segments
Exhibit 55: Agios Inc. - Key offerings
Exhibit 56: Agios Inc. - Segment focus
10.5 Astellas Pharma Inc.
Exhibit 57: Astellas Pharma Inc. - Overview
Exhibit 58: Astellas Pharma Inc. - Product and service
Exhibit 59: Astellas Pharma Inc. - Key offerings
10.6 Bristol Myers Squibb Co.
Exhibit 60: Bristol Myers Squibb Co. - Overview
Exhibit 61: Bristol Myers Squibb Co. - Product and service
Exhibit 62: Bristol Myers Squibb Co. - Key offerings
10.7 Daiichi Sankyo Co. Ltd.
Exhibit 63: Daiichi Sankyo Co. Ltd. - Overview
Exhibit 64: Daiichi Sankyo Co. Ltd. - Business segments
Exhibit 65: Daiichi Sankyo Co. Ltd. - Key offerings
Exhibit 66: Daiichi Sankyo Co. Ltd. - Segment focus
10.8 F. Hoffmann La Roche Ltd.
Exhibit 67: F. Hoffmann La Roche Ltd. - Overview
Exhibit 68: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 69: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 70: F. Hoffmann La Roche Ltd. - Segment focus
10.9 GlaxoSmithKline Plc
Exhibit 71: GlaxoSmithKline Plc - Overview
Exhibit 72: GlaxoSmithKline Plc - Business segments
Exhibit 73: GlaxoSmithKline Plc - Key offerings
Exhibit 74: GlaxoSmithKline Plc - Segment focus
10.10 Novartis AG
Exhibit 75: Novartis AG - Overview
Exhibit 76: Novartis AG - Business segments
Exhibit 77: Novartis AG - Key offerings
Exhibit 78: Novartis AG - Segment focus
10.11 Pfizer Inc.
Exhibit 79: Pfizer Inc. - Overview
Exhibit 90: Pfizer Inc. - Product and service
Exhibit 91: Pfizer Inc. - Key News
Exhibit 92: Pfizer Inc. - Key offerings
10.12 Teva Pharmaceutical Industries Ltd.
Exhibit 93: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 94: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 95: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 96: Teva Pharmaceutical Industries Ltd. - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 97: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 98: Research Methodology
Exhibit 99: Validation techniques employed for market sizing
Exhibit 100: Information sources
11.4 List of abbreviations
Exhibit 101: List of abbreviations
About Us:
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article